Piper Jaffray Upgrades Vertex Pharmaceuticals To Overweight

Analysts at Piper Jaffray upgraded Vertex Pharmaceuticals

from Neutral to Overweight. The price target for Vertex Pharmaceuticals has been raised from $87.50 to $125. Vertex Pharma shares have gained 42.08% over the past 52 weeks, while the S&P 500 index has surged 11.46% in the same period. Vertex Pharmaceuticals' shares fell 0.51% to close at $104.73 on Friday.